Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Quantitative systems pharmacology modeling of macrophage‐targeted therapy combined with PD‐L1 inhibition in advanced NSCLC

Clinical and Translational Science(2024)10.1111/cts.13811Source: DataRank Database

Quantitative systems pharmacology modeling of macrophage‐targeted therapy combined with PD‐L1 inhibition in advanced NSCLC is a research paper published in Clinical and Translational Science (2024). On theSindex it has a DataRank of 0. It has been cited 13 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access13 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.37)OA: goldTopics (66)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Theinmozhi Arulraj ORCID,Samira Anbari ORCID,Aleksander S. Popel ORCID,Hanwen Wang ORCID

Live enrichment

PubMed:38814167 PMC:PMC11138134 OpenAlex:https://openalex.org/W4399175659

National Institutes of Health

Grant: R01CA138264

National Institutes of Health

Grant: 5R01CA138264-13

Predictive experiment-based multiscale models of the tumor immune microenvironment and immunotherapy in breast cancer

FWCI

2.37

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

goldLicense: cc-by-nc

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cts.13811

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cts.13811

publisherhttps://ascpt.onlinelibrary.wiley.com/doi/pdf/10.1111/cts.13811

journalhttps://doi.org/10.1111/cts.13811

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38814167

Fields of Study

Cancer Immunotherapy and BiomarkersImmune cells in cancerPhagocytosis and Immune Regulation03 medical and health sciences0302 clinical medicineHumansCarcinoma, Non-Small-Cell LungLung NeoplasmsImmune Checkpoint InhibitorsB7-H1 AntigenAntineoplastic Combined Chemotherapy ProtocolsCD47 AntigenMacrophagesReceptors, CCR2Network PharmacologyComputer SimulationModels, BiologicalTumor-Associated Macrophages

MeSH Terms

Immune Checkpoint InhibitorsTumor-Associated MacrophagesNetwork PharmacologyAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungComputer SimulationHumansLung NeoplasmsMacrophagesModels, BiologicalCD47 AntigenReceptors, CCR2B7-H1 Antigen

Keywords

MedicinePharmacokineticsBlockadePharmacodynamicsPharmacologyCombination therapyOncologyImmune systemSystems pharmacologynon-small cell lung cancer (NSCLC)Clinical trialLung cancerDrugInternal medicineImmunologyReceptorA549 cellLung NeoplasmsReceptors, CCR2MacrophagesCD47 AntigenRM1-950Network PharmacologyModels, BiologicalB7-H1 AntigenCarcinoma, Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsTumor-Associated MacrophagesHumansBrief ReportsComputer SimulationTherapeutics. PharmacologyPublic aspects of medicineRA1-1270Immune Checkpoint Inhibitors

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being